ProKidney (PROK) shares were up more than 80% after the company said its investigational therapy rilparencel stabilized kidney function in a group of patients with chronic kidney disease and diabetes who received two injections about three months apart in a phase 2 trial, replicating the dosing regimen of its ongoing phase 3 study.

http://www.mtnewswires.com
Copyright © 2025 MT Newswires. All rights reserved. MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.